Alda Pharmaceuticals (APCSF)

[woodstock135]

ALDA Receives Registration for Hydrocortisone Ointment(ccnm)
VANCOUVER, BRITISH COLUMBIA--(Marketwire - Sept. 8, 2011) -ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the "Company" or"ALDA") announces that Natural Product Number ("NPN") 80026033 has been issuedfor a 0.5% hydrocortisone (0.5% HC) ointment. The Company is authorized to sellthis product in Canada for temporary relief of minor skin irritations, rashes,itching and redness due to eczema, insect bites, poison ivy and other irritatingplants; contact dermatitis caused by soaps, detergents, cosmetics, jewellery andother materials that irritate the skin; seborrheic dermatitis and psoriasis.
Typically, skin conditions of these types (which affect over 75% of Canadianadults at one time or another) begin as an inflammatory condition, but are oftenworsened or prolonged by secondary infection with bacteria or fungi (such as thefungi that causes athlete's foot). The combination of an effectiveanti-microbial product (such as the T36® formulation) withan anti-inflammatory agent (such as 0.5% hydrocortisone) would address thiscommon medical condition more effectively and make treatment recommendationsmore straightforward for the health care provider and much easier to carry outfor the patient. This innovative combination of an anti-microbial andanti-inflammatory therapy (avoiding the need to apply separate products to treata single condition) represents an important step forward in the non-prescriptiontherapeutic market. It is also consistent with the current approach favoured bya number of health providers encouraging Canadians to take charge in a positiveway of their own care. Obtaining registration of a hydrocortisone ointment is afirst step for the Company in bringing this approach to market.
About ALDA Pharmaceuticals Corp.
ALDA is focused on the development of infection-control therapeutics derivedfrom its patented T36® technology. The Company trades onthe TSX Venture Exchange under the symbol APH.
Terrance G. Owen, Ph.D., MBA, President & CEO
ALDA Pharmaceuticals Corp.